Prolonged anti-diabetic effect of fibroblast growth factor 1 (fgf1)
AssigneeUniversity of Washington
InventorsMichael W. SCHWARTZ, Jarrad SCARLETT
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions and methods for inducing sustained diabetes remission by single administration of FGF1 to the brain. The composition and methods described herein result in basal glucose clearance by using a dosage of FGF1 that is lower than that needed for systemic efficacy and is devoid of the risk of hypoglycemia and changes in body weight, food intake, hepatic glucose production, insulin secretion or insulin sensitivity.
Claims31
A pharmaceutical composition comprising a unit dose of Fibroblast Growth Factor 1 (FGF1) polypeptide preparation comprising a pharmaceutically acceptable carrier and formulated for administration to the brain
(canceled)
7-10. (canceled)
17-20. (canceled)
(canceled)
(canceled)
27-30. (canceled)
(canceled)
(canceled)
35-42. (canceled)
44-52. (canceled)
A method to treat high blood glucose levels in a subject in need thereof, comprising administering a therapeutically effective amount of an FGFR binding protein to the brain of the subject to normalize the blood glucose levels to normal range, wherein the FGFR is selected from the group, FGFR1, FGFR2, FGFR3, FGFR4 or a combination thereof.
55-74. (canceled)
Dependencies are inferred from the claim text.